Item 1.01 Entry Into A Material Definitive Agreement.






Amendment to Merger Agreement

On October 16, 2020, Helix Technologies, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Forian Inc., a Delaware corporation ("Parent"), DNA Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), and Medical Outcomes Research Analytics, LLC, a Delaware limited liability company ("MOR").

Pursuant to Section 8.04 of the Merger Agreement, the Merger Agreement may be amended by the parties. On December 30, 2020, the Merger Agreement was amended as follows:

1. The phrase "will be converted into the right to receive 0.02731 validly


    issued, fully paid and non-assessable share of Parent Common Stock (the
    "Merger Consideration")" in Section 2.01(c) of the Merger Agreement was
    deleted and replaced in its entirety by "will be converted into the right to
    receive 0.05 validly issued, fully paid and non-assessable share of Parent
    Common Stock (the "Merger Consideration")".

2. The phrase "will be exchanged for shares of Parent Common Stock at an average


    exchange ratio of 0.9709" in Section 3.03(c) of the Merger Agreement was
    deleted and replaced in its entirety by "will be exchanged for shares of
    Parent Common Stock at an average exchange ratio of 1.7776".

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.   Description

2.2             Amendment to Agreement and Plan of Merger, dated as of December 30,
              2020, by and among Helix Technologies, Inc., Forian Inc., DNA Merger
              Sub, Inc. and Medical Outcomes Research Analytics, LLC




                                       1

© Edgar Online, source Glimpses